FDA approves Citius Pharmaceuticals' blood cancer therapy, Lymphir, for relapsed cutaneous T-cell lymphoma patients.

The FDA has approved Citius Pharmaceuticals' blood cancer therapy, Lymphir, for relapsed cutaneous T-cell lymphoma patients who have already received one prior systemic therapy, marking the first indication for Lymphir and Citius Pharmaceuticals' first FDA-approved product. Lymphir targets the interleukin-2 receptor on malignant T-cells and Tregs, offering a novel approach to treating CTCL and is expected to launch in the U.S. market within the next five months. The overall market for CTCL treatments is estimated to be around $300-400 million.

August 08, 2024
12 Articles

Further Reading